These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 15983962)

  • 1. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study.
    Shavit L; Neykin D; Lifschitz M; Slotki I
    Clin Nephrol; 2011 Nov; 76(5):388-95. PubMed ID: 22000559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.
    Feniman-De-Stefano GM; Zanati-Basan SG; De Stefano LM; Xavier PS; Castro AD; Caramori JC; Barretti P; Franco RJ; Martin LC
    Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):158-67. PubMed ID: 26116627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
    J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone excess or escape: Treating resistant hypertension.
    Ubaid-Girioli S; Adriana de Souza L; Yugar-Toledo JC; Martins LC; Ferreira-Melo S; Coelho OR; Sierra C; Coca A; Pimenta E; Moreno H
    J Clin Hypertens (Greenwich); 2009 May; 11(5):245-52. PubMed ID: 19534021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension, angiotensin II, aldosterone, and race.
    Ben-Yehuda O
    J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical implications of aldosterone blockade.
    Weber MA
    Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients.
    Ishimitsu T; Ohta S; Ohno E; Takahashi T; Numabe A; Okamura A; Ohba S; Hashimoto A; Matsuoka H
    Ther Apher Dial; 2013 Oct; 17(5):524-31. PubMed ID: 24107281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
    Sato A; Fukuda S
    Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients.
    Yongsiri S; Thammakumpee J; Prongnamchai S; Tengpraettanakorn P; Chueansuwan R; Tangjaturonrasme S; Dinchuthai P
    Ther Apher Dial; 2015 Feb; 19(1):81-6. PubMed ID: 25196890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
    Tanabe A; Naruse M; Hara Y; Sato A; Tsuchiya K; Nishikawa T; Imaki T; Takano K
    J Hypertens; 2004 May; 22(5):1017-23. PubMed ID: 15097243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.